Navigation Links
Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 September 2009
Date:11/11/2009

KVISTGARD, Denmark, November 11 /PRNewswire-FirstCall/ -- Today Bavarian Nordic published the company's third quarterly report 2009. The full report including the financial statements is available on the company's website: http://www.bavarian-nordic.com.

In the first nine months of 2009 Bavarian Nordic generated revenue of DKK 53 million and recorded a loss before tax of DKK 261 million. As of 30 September 2009 the Group's net free liquidity was DKK 304 million The company maintains its expectations for the financial result for the full year 2009 with revenues in the range of DKK 100-300 million and a pre-tax loss of between DKK 275-325 million. A prerequisite for maintaining the high end of the guidance is that the company will receive delivery allowance from the US authorities no later than beginning of December, leading to the possible initiation of deliveries of IMVAMUNE(R) to the US Government before the end of 2009. The net free liquidity at year-end is expected to be approximately DKK 175 million as a potential delivery to the US Government by late 2009 will not have a cash effect in 2009.

Following the FDA inspection of the IMVAMUNE(R) manufacturing facilities in May, Bavarian Nordic has made progress in the implementation of the corrective actions as required due to observations made by the FDA. The company expects to finalise its responses to the FDA no later than in the beginning of December and subsequently will await the FDA review and acceptance hereof. Consequently, the company maintains its expectations to initiate delivery of IMVAMUNE(R) to the US government before the end of second quarter of 2010.

During the first nine months of 2009, Bavarian Nordic reported further confirmatory data on PROSTVAC(TM), the company's late-stage prostate cancer vaccine candidate. Oral presentations were held at several cancer congresses, including ASCO and ECCO annual meetings.
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Bavarian Nordic Has Signed Contract With an EU Country for the Delivery of IMVAMUNE(R)
2. Bavarian Nordic A/S - Half Year Interim Report 2009
3. Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R)
4. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
5. Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009
6. Bavarian Nordic Publishes its Annual Results 2008
7. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
8. Bavarian Nordics Case Against Oxford BioMedica
9. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
10. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
11. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 PuraMed BioScience ... and marketer of over-the-counter (OTC) medicinal and healthcare ... opinion on the company based on low market ... , Non-Prescription, All Natural Product to Treat Migraine ... Outperforms #1 Prescription Competitor , Currently Available ...
(Date:5/23/2013)... 23, 2013  Saddleback Memorial Medical Center in ... first hospital on the West Coast to perform a ... option provides women with a state-of-the-art, minimally invasive approach ... Winter , M.D., a highly regarded ... director of minimally invasive surgery at Saddleback Memorial, led ...
(Date:5/23/2013)... -- Northwest Biotherapeutics (NASDAQ: NWBO ) (NW ... immune therapies for solid tumor cancers, announced today that ... Society Of Clinical Oncology (ASCO) meeting in ... immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ) ... conference focused on clinical treatment of cancer, with attendance ...
(Date:5/23/2013)... Korea , May 23, 2013 ... SillaJen, Inc., a private biotherapeutics and contract research ... biological products for cancer, announced today a publication ... patients treated with the oncolytic and immunotherapeutic vaccinia ... This research was published in the May 15 ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... Oct. 27 eBioscience Corporation today announced that ... Bender MedSystems GmbH in an all cash transaction. ... high profile immunology and oncology products including the ... life sciences and diagnostics markets. , "Bender MedSystems ...
... Medivation, Inc. (Nasdaq: MDVN) today announced that it will ... October 27, to discuss partnering plans for MDV3100, Medivation,s investigational ... treatment of prostate cancer. , Teleconference/Webcast Details ... October 27, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific ...
... Champions Biotechnology, Inc. (OTC Bulletin ... aimed at accelerating the development and enhancing the value ... Biotech Oncology Research & Development, a Division of Janssen ... oncology therapeutic in Champions, Biomerk Tumorgraft(TM) platform. ...
Cached Biology Technology:eBioscience Acquires Bender MedSystems; Business Combination Adds Cutting-Edge Product Lines and Expands International Operations 2eBioscience Acquires Bender MedSystems; Business Combination Adds Cutting-Edge Product Lines and Expands International Operations 3Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM) 2Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM) 3
(Date:5/23/2013)... School of Public Health at Emory University, along ... have received a $4 million grant over four ... University (Health and Exposome Research Center: Understanding Lifetime ... grant awarded in the United States. , ... Institute of Environmental Health Sciences (NIEHS) of the ...
(Date:5/23/2013)... undergo surgery or harsh treatments because science fails ... forms of the disease. Researchers at Case Western ... developing technology that allows patients to safely choose ... or take drastic measures. , The project is ... of biomedical engineering at Case Western Reserve and ...
(Date:5/23/2013)... Frontiers, one of the world,s largest and fastest ... new journal, Frontiers in Bioengineering and Biotechnology ... all specialties, Frontiers in Bioengineering and Biotechnology ... diverse and emerging bioengineering and biotechnology research to ... in Bioengineering and Biotechnology will provide an ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3Frontiers launches new open-access journal in Bioengineering and Biotechnology 2
... a cabbage-eating moth may one day provide a safer, target-specific ... , They compared the ability of the four best-characterized jumping ... and produce a desired change, such as making the cell ... piggyBac transposon was five to 10 times better than the ...
... the largest HIV/AIDS therapy studies conducted to date ... therapy more than doubles the risk of AIDS ... the Mailman School of Public Health and Harlem ... known as Strategies for Management of Anti-Retroviral Therapies, ...
... may be placing their unborn children at increased risk ... study of construction workers in the Netherlands, conducted in ... links low birth weight and birth defects to paternal, ... and cleansers. , The study, although preliminary in its ...
Cached Biology News:Jumping gene could provide non-viral alternative for gene therapy 2Jumping gene could provide non-viral alternative for gene therapy 3Study shows interruption of antiretroviral therapy increases risk of disease and death 2Study shows interruption of antiretroviral therapy increases risk of disease and death 3Solvent exposure linked to birth defects in babies of male painters 2
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Rsk2/MAPKAP Kinase 1b, #0 SK2/MAPKAP K1 beta Smartpool&t 3T3 cell lysate Non-specific Control Pool , #D 1X Universal Buffer...
Request Info...
Assay Kit formatted for flow cytometric detection of levels of phosphorylated histone H2A.X....
Biology Products: